SEARCH

SEARCH BY CITATION

References

  • 1
    Brattsand R. Overview of newer glucocorticoid preparations for IBD. Can J Gastroenterol 1990; 4: 40714.
  • 2
    Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. (The Global Budesonide Study Group.) Gut 1997; 41: 20914.
  • 3
    Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide CIR for maintenance of remission in ileocecal Crohn's disease. A European multicentre placebo controlled trial for 12 months. Gastroenterology 1994; 106 (No 4 Part 2): A722(Abstract).
  • 4
    Thomsen OØ, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide–Mesalamine Study Group. N Engl J Med 1998; 339: 3704.
  • 5
    Edsbäcker S. Budesonide capsules: scientific basis. Drugs of Today 2000; 36(Suppl. G): 923.
  • 6
    Wikberg M, Ulmius J, Ragnarsson G. Review article: targeted drug delivery in treatment of intestinal diseases. Aliment Pharmacol Ther 1997; 11(Suppl. 3): 10915.
  • 7
    Sciarretta G, Furno A, Mazzoni M, Ferrieri A, Malaguti P. Scintigraphic study of gastrointestinal transit and disintegration of mesalazine tablets labeled with technetium-99m. Scand J Gastroenterol 1993; 28: 7835.
  • 8
    Steed KP, Hooper G, Monti N, Strolin Benedetti M, Fornasini G, Wilding IR. The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system (‘TIME CLOCK®’ system). J Controlled Release 1997; 49: 11522.
  • 9
    Hardy JG, Healy JNC, Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1987; 1: 27380.
  • 10
    Kenyon CJ, Nardi RV, Wong D, Hooper G, Wilding IR, Friend DR. Colonic delivery of dexamethasone: a pharmacoscintigraphic evaluation. Aliment Pharmacol Ther 1997; 11: 20513.
  • 11
    Healey JNC. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease. Scand J Gastroenterol 1990; 25(Suppl. 172): 4751.
  • 12
    Wilding IR, Coupe AJ, Davis SS. The role of α-scintigraphy in oral drug delivery. Advanced Drug Delivery Reviews 2001; 46: 10324.
  • 13
    Lindberg C, Blomqvist A, Paulson J. Determination of (22 R,S) budesonide in human plasma by automated liquid chromatography/thermospray mass spectrometry. Biol Mass Spectrom 1992; 21: 52533.
  • 14
    Borgå O, Ekman I, Pedersen S, Steffensen G, Tönnesson M. Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol 1987; 31(5): 57982.
  • 15
    Paulsson J, Lindberg C. Increasing thermospray response for cortisol by derivatization. J Chromatogr 1991; 554: 14954.
  • 16
    Proost J. The application of numerical deconvolution technique in the assessment of bioavailability. J Pharm Sci 1985; 74(10): 11356.
  • 17
    Nyberg L, Vatn M, Aasen S, Pallant D, Jacobsen M, Rootwelt K. Uptake of budesonide from ileum, cecum, and proximal colon studied by means of an intestinal telemetric remote-release capsule. Gastroenterology 1999; 116(4 Part 2): A786(Abstract).
  • 18
    Kaiser H, Aaronson D, Dockhorn R, Edsbäcker S, Korenblat P, Källén A. Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. Br J Clin Pharmacol 1999; 48(3): 30916.
  • 19
    Edsbäcker S, Nilsson M, Larsson P. A cortisol suppression dose–response comparison of budesonide in controlled ileal release capsules with prednisolone. Aliment Pharmacol Ther 1999; 13: 21924.
  • 20
    Edsbäcker S, Larsson P, Wollmer P. Gut delivery of budesonide, a topically active corticosteroid, from plain and controlled-release capsules. Eur J Gastroenterol Hepatol 2002; 14: 16.
  • 21
    Cvetkovic S, Edsbäcker S, Ejerblad S, Ekman I, Kågedal M. Intraluminal concentrations of budesonide following administration of Entocort capsules in subjects with ileostomy. Gut 1997; 41(Suppl. 3): A222(Abstract).
  • 22
    Miller LR, Vitti R, Maurer A, et al. Small intestinal transit in symptomatic Crohn's disease. Gastroenterology 1989; 96: A344(Abstract).
  • 23
    Hebden JM, Blackshaw PE, Perkins AC, Wilson CG, Spiller RC. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2000; 14(2): 15561.
  • 24
    Ryrfeldt Å, Andersson P, Edsbäcker S, Tönnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63(Suppl. 122): 8695.
  • 25
    Dahlström K, Edsbäcker S, Källen A. Rectal pharmacokinetics of budesonide. Eur J Clin Pharmacol 1996; 49: 2938.
  • 26
    Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 1992; 21: 51126.
  • 27
    Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283(3): 155262.
  • 28
    Lundin P, Naber T, Nilsson M, Edsbäcker S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease. Aliment Pharmacol Ther 2001; 15(1): 4551.
  • 29
    Lundin P, Lindquist B, Persson T, Edsbäcker S. Pharmacokinetics of budesonide in children and adults with Crohn's disease given budesonide capsules (Entocort EC). Gastroenterology 2002; 122(Suppl. 1): W1001.
  • 30
    Naber TH, Olaison G, Smedh K, Jansen JB, Sjödahl R. Pharmacokinetics of budesonide controlled ileal release capsules in active Crohn's disease. Gastroenterology 1996; 110(Suppl. 4): A977(Abstract).
  • 31
    Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metabolism Disposition 2001; 29(3): 20712.
  • 32
    Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27: 88692.